Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness

Thursday, June 20, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences has announced the expansion of its Hepatitis Scientific Advisory Board with the addition of Dr. Mark Sulkowski and Dr. Jordan Feld. This move comes as the company approaches clinical readiness for its PBGENE-HBV program, which aims to utilize its proprietary ARCUS platform for gene editing therapies. The inclusion of these world-class clinical investigators is expected to enhance the program's development.
Price reaction · baseline $10.1 (2024-06-18 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close · peak
-3.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Expansion of the Scientific Advisory Board with renowned experts.
  • Near clinical readiness of the PBGENE-HBV program.
  • Utilization of advanced gene editing technology.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Jun. 20, 2024– Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision,

Frequently Asked Questions

Who joined the Precision BioSciences advisory board?

Dr. Mark Sulkowski and Dr. Jordan Feld have joined the advisory board.

What is the focus of the PBGENE-HBV program?

The PBGENE-HBV program focuses on developing gene editing therapies for hepatitis.

What technology does Precision BioSciences use?

Precision BioSciences utilizes its proprietary ARCUS platform for gene editing.

Why is the advisory board expansion significant?

The expansion brings in world-class clinical investigators to enhance program development.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences Hepatitis Mark Sulkowski Jordan Feld PBGENE-HBV
Last updated: Jun 20, 2024

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →